"Overview of Adult ADHD
Attention deficit/hyperactivity disorder (ADHD) is a mental health disorder that is usually diagnosed during childhood. According to The American Psychiatric Association, 5% of children in the U.S. have ADHD, a"...
Post-marketing reports of guanfacine overdosage indicate that hypotension, drowsiness, lethargy, and bradycardia have been observed following overdose. Initial hypertension may develop early and may be followed by hypotension. Similar symptoms have been described in voluntary reports to the American Association of Poison Control Center's National Poison Data System. Miosis of the pupils may be noted on examination. No fatal overdoses of guanfacine have been reported in published literature.
Consult a Certified Poison Control Center by calling 1-800-222-1222 for up to date guidance and advice.
Management of INTUNIV® overdose should include monitoring for and the treatment of initial hypertension, if that occurs, as well as hypotension, bradycardia, lethargy and respiratory depression. Children and adolescents who develop lethargy should be observed for the development of more serious toxicity including coma, bradycardia and hypotension for up to 24 hours, due to the possibility of delayed onset hypotension.
Patients with a history of hypersensitivity to INTUNIV®, its inactive ingredients [see DESCRIPTION] or other products containing guanfacine should not take INTUNIV®.
Last reviewed on RxList: 9/9/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Intuniv Information
Intuniv - User Reviews
Intuniv User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.